Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer Funds its First Selection of Five Late-Stage Projects

Published: Friday, December 14, 2012
Last Updated: Friday, December 14, 2012
Bookmark and Share
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities has announced that it has provided funding for its first five late-stage internal research projects.

This funding will enable Curie’s scientists to gather more evidence and progress with the selected projects, making their research more attractive to industrial companies.

Curie-Cancer has a research budget dedicated to funding for late-stage projects at a rate of EUR 50,000 to EUR 150,000 per project.

The aim of this funding is to help secure additional proofs of concept for already patented technologies whose immaturity acts as a brake when it comes to transferring them to the industry.

“The available research funding has enabled Curie-Cancer to react quickly and support our first five projects at the critical time it is needed,” said Damien Salauze, director, Curie-Cancer.

Salauze continued, “During the current economic climate, the demand by the market for additional proofs of concept is increasing. Curie-Cancer now has both the financial and intellectual resources to know what is required and to provide that additional research. We will continue to select and help projects to reach both the market and patients.”

Among the technologies to have benefited from this type of funding in 2012, Curie-Cancer supported the following:
• A method for evaluating the efficacy of two molecules from the Institut Curie’s library of chemical entities that act on two innovative targets, respectively Nuak-1 and GCK. These are kinases that are particularly involved in certain tumoral processes.

The funding provided made it possible to develop a more accurate profile of the therapeutic targets with which these molecules interact and also to test their efficacy on an additional number of cancer cell lines.

The next stage will be to validate this information in animal models, especially in mice that are xenografted with sections of tumor extracted from patients in the Institut Curie’s operating theatres. Patent applications have been submitted for both these molecules.

• A technique for studying the pharmacokinetic and pharmacological properties of a telomestatin analog. This compound, which also comes from the Institut Curie’s library of chemical entities, has the characteristic of interfering with the protection mechanisms of telomeres (which are located on the edge of chromosomes), thereby inducing the death of cancer cells whose telomere protection mechanisms are known to be more sensitive than those of normal cells.

The funding provided made it possible to determine the best possible conditions for administering this compound in animal models (formulation, metabolization, etc.) and then to measure its degree of efficacy in models of xenografted mice.

• A method for validating a signature that makes it possible to identify those patients suffering from bladder cancer for whom a particular medicine is likely to be effective. A patent application is in the process of being filed for this signature.

However, the industrial companies sounded out within the framework of confidentiality agreements think the number of tumor samples on which the conclusions are based is insufficient and that studies need to be conducted on at least 400 samples rather than the 150 used to date.

The support provided by Curie-Cancer is going to finance this additional work, which will strengthen the patent application and subsequently facilitate the transfer of this technology to an industrial partner.

The technologies that can benefit from such funding are selected by Curie-Cancer, usually after being presented to an initial group of potential industrial partners.

The comments made by the potential partners during the presentation help define the extent of the additional work required. The Strategic Orientation Committee of the Institut Curie, comprising representatives from large companies, intermediate firms to small and medium-sized enterprises, gives a final approval on the selection.

The committee also matches that approval to confidential information on industrial companies’ expectations.

“The procedures that have been put in place by Curie-Cancer are critical to the decision-making process of whom to fund,” said Damien Salauze, director, Curie-Cancer.

Salauze continued, “The input of both the industrial partners and the Strategic Orientation Committee of the Institut Curie is combined with the expertise of Curie-Cancer scientists and doctors. This creates a resource to determine what convincing information is still required by industrial companies and what experiments still need to be carried out. The beneficiaries of this are not just the market, but also patients waiting for treatments.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Biolog-id Sign Partnership Agreement
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.
Wednesday, June 05, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
Tuesday, April 16, 2013
Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.
Wednesday, January 30, 2013
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!